Imperial College London
Alternate

ProfessorAndreaFrilling

Faculty of Medicine, Department of Surgery & Cancer

Chair in Endocrine Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 3210a.frilling

 
 
//

Location

 

BN2/13 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Oberg:2020:10.1016/j.annonc.2019.11.003,
author = {Oberg, K and Califano, A and Strosberg, JR and Ma, S and Pape, U and Bodei, L and Kaltsas, G and Toumpanakis, C and Goldenring, JR and Frilling, A and Paulson, S},
doi = {10.1016/j.annonc.2019.11.003},
journal = {Annals of Oncology},
pages = {202--212},
title = {A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood},
url = {http://dx.doi.org/10.1016/j.annonc.2019.11.003},
volume = {31},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundThe lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease has hindered management. The advance of genomic medicine and the development of molecular biomarkers has provided a strategy—liquid biopsy—to facilitate real-time management. We reviewed the role of a blood mRNA-based NET biomarker, the NETest, as an in vitro diagnostic (IVD).Patients and methodsA systematic review of the literature using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was undertaken. The methodological quality was evaluated using the QUADAS-2 tool. We identified ten original scientific papers that met the inclusion criteria. These were assessed by qualitative analysis and thereafter meta-analysis. Data were pooled and a median [95% confidence interval (CI)] diagnostic odds ratio (DOR), positive likelihood ratio (+LR), and negative likelihood ratio (−LR) were calculated. For the meta-analysis, a generic inverse variance method was undertaken using the accuracy and area under the curve (AUC) data.ResultsThe ten studies exhibited moderate to high methodological quality. They evaluated NETest usage both as a diagnostic and as a monitoring tool. The meta-analysis identified the diagnostic accuracy of the NETest to be 95%–96% with a mean DOR of 5 853, +LR of 195, and −LR of 0.06. The NETest was 84.5%–85.5% accurate in differentiating stable disease from progressive disease. As a marker of natural history, the accuracy was 91.5%–97.8%. As an interventional/response biomarker, the accuracy was 93.7%–97.4%. The pooled AUC for the NETest was 0.954 ± 0.005, with a z-statistic of 175.06 (P < 0.001).ConclusionsThe NETest is an accurate biomarker suitable for clinical use in NET disease management. The meta-analysis supports the utility of the NETest as an IVD to establish a diagnosis and monitor therapeutic efficacy. The use of this as a biomarker provides information relevan
AU  - Oberg,K
AU  - Califano,A
AU  - Strosberg,JR
AU  - Ma,S
AU  - Pape,U
AU  - Bodei,L
AU  - Kaltsas,G
AU  - Toumpanakis,C
AU  - Goldenring,JR
AU  - Frilling,A
AU  - Paulson,S
DO  - 10.1016/j.annonc.2019.11.003
EP  - 212
PY  - 2020///
SN  - 0923-7534
SP  - 202
TI  - A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
T2  - Annals of Oncology
UR  - http://dx.doi.org/10.1016/j.annonc.2019.11.003
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000516712400008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S0923753419390842?via%3Dihub
VL  - 31
ER  -
Download